Boundless Bio, Inc. Common Stock Cash Flow-to-Debt Ratio
Boundless Bio, Inc. Common Stock cash flow-to-debt ratio. Boundless Bio, Inc. Common Stock (BOLD) has a Cash Flow-to-Debt Ratio of -0.17x as of September 2025, meaning its operating cash flow of $-10.20 Million could theoretically repay 0% of its total liabilities ($58.55 Million) in one year. See Boundless Bio, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Boundless Bio, Inc. Common Stock (2016–2024)
Cash flow-to-debt ratio of Boundless Bio, Inc. Common Stock from 2016 to 2024. Historical debt coverage capacity for Boundless Bio, Inc. Common Stock across 7 annual periods. Also explore Boundless Bio, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Boundless Bio, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2016–2024)
Boundless Bio, Inc. Common Stock cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Boundless Bio, Inc. Common Stock. For the full cash flow conversion analysis, see Boundless Bio, Inc. Common Stock (BOLD) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.09x | $-60.84 Million | $55.77 Million | ▼ -498.4% |
| 2023 | -0.18x | $-46.85 Million | $256.98 Million | ▲ +27.0% |
| 2022 | -0.25x | $-39.60 Million | $158.53 Million | ▼ -63.2% |
| 2021 | -0.15x | $-23.25 Million | $151.91 Million | ▲ +95.8% |
| 2018 | -3.62x | $-107.98 Million | $29.80 Million | ▲ +5.4% |
| 2017 | -3.83x | $-84.51 Million | $22.06 Million | ▼ -77.3% |
| 2016 | -2.16x | $-49.02 Million | $22.69 Million | — |